

July 17, 2018

Sawai Pharmaceutical Co., Ltd.

Upsher-Smith Laboratories, LLC

**UPSHER-SMITH LAUNCHES VIGABATRIN FOR ORAL SOLUTION UNDER THE  
BRAND NAME VIGADRONE™**

*- Offers Patients and Physicians a Fully Substitutable Generic Alternative with  
Brand-Quality Support -*

Maple Grove, MN –July 16, 2018 – Upsher-Smith Laboratories, LLC (Upsher-Smith, President and CEO: Rusty Field), a subsidiary of Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) announced the launch of Vigadrone™ (vigabatrין)\* for oral solution, 500 mg, a fully substitutable, generic version of Sabril® (vigabatrין) powder for oral solution.\*\* Vigadrone™ is prescribed for Infantile Spasm (IS) or Refractory Complex Partial Seizures (CPS). The product was approved by the U.S. Food and Drug Administration (FDA) on June 21, 2018.

The Vigabatrין powder market had U.S. sales of approximately \$333 million for the 12 months ending December 31, 2017 according to IQVIA.

\* Vigadrone™ is a trademark of Upsher-Smith Laboratories, LLC.

\*\* Sabril® is a registered trademark of Lundbeck.

**About Upsher-Smith**

Upsher-Smith Laboratories, LLC is a trusted U.S. pharmaceutical company that has strived to deliver quality, affordable generic medications for nearly a century. In June 2017, Upsher-Smith was acquired by Sawai Pharmaceutical Co., Ltd., a large publicly traded generics company in Japan that had been seeking entry into the U.S. market. Upsher-Smith and Sawai share a strikingly similar family history and hold many of the same cherished goals and values— most importantly, the philosophy of always putting patients first. Upsher-Smith will continue to do those things it does best, which is provide a consistent supply of quality, affordable medications and invest in its historically strong industry relationships. Ultimately, Upsher-Smith believes the acquisition by Sawai represents a tremendous opportunity to leverage each company for growth worldwide and embark together on an exciting new chapter in generics. For more information, visit <https://www.upsher-smith.com/>

---

◆ Contact information ◆

PR / IR Group, Corporate Strategy Department, Sawai Pharmaceutical Co., Ltd.

E-mail : [koho@sawai.co.jp](mailto:koho@sawai.co.jp)